Journal Article

Assessing the impact of digital patient monitoring on health outcomes and healthcare resource usage in addition to the feasibility of its combination with at-home treatment, in participants receiving systemic anticancer treatment in clinical practice: protocol for an interventional, open-label, multicountry platform study (ORIGAMA)

Eicher, Manuela, Welslau, Manfred, Balas, Bogdana, Bustillos, Alberto, Golding, Sophie, Iivanainen, Sanna, Baird, Anne-Marie, Castro Sanchez, Amparo Yovanna, Reig, Maria, Mueller-Ohldach, Mathis, Ammann, Johannes

2023

Overview

IntroductionDigital patient monitoring (DPM) tools can enable more effective clinical care and improved patient outcomes in cancer. However, their broad adoption requires ease of use and demonstration of real-world clinical utility/impact. ORIGAMA (MO42720) is an interventional, open-label, multicountry platform study investigating the clinical utility of DPM tools and specific treatments. ORIGAMA will begin with two cohorts that aim to assess the impact of the atezolizumab-specific Roche DPM Module (hosted on the Kaiku Health DPM platform (Helsinki, Finland)) on health outcomes and healthcare resource usage, and its feasibility to support at-home treatment administration, in participants receiving systemic anticancer treatment. Other digital health solutions may be added to future cohorts.Methods and analysisIn Cohort A, participants with metastatic non-small cell lung cancer (NSCLC), extensive-stage SCLC or Child Pugh A unresectable hepatocellular carcinoma will be randomised to a locally approved anticancer regimen containing intravenous atezolizumab (TECENTRIQ, F. Hoffmann-La Roche Ltd/Genentech) and local standard-of-care support, with/without the Roche DPM Module. Cohort B will assess the feasibility of the Roche DPM Module in supporting administration of three cycles of subcutaneous atezolizumab (1875 mg; Day 1 of each 21-day cycle) in the hospital, followed by 13 cycles at home by a healthcare professional (ie, flexible care), in participants with programmed cell-death ligand 1-positive, early-stage NSCLC. The primary endpoints are the mean difference in change of the participant-reported Total Symptom Interference Score at Week 12 from baseline (Cohort A) and flexible care adoption rate at Cycle 6 (Cohort B).Ethics and disseminationThis study will be conducted according to the Declaration of Helsinki, and/or the applicable laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the individual. The study received its first Ethics Committee approval in Spain in October 2022. Participants will provide written informed consent in a face-to-face setting. The results of this study will be presented at national and/or international congresses and disseminated via publication in peer-reviewed journals.Trial registration numberNCT05694013.

• Publisher: British Medical Journal Publishing Group,BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Breast cancer / Cancer therapies / Carcinoma, Non-Small-Cell Lung - drug therapy / Chemotherapy / Clinical outcomes / Delivery of Health Care / FDA approval / Feasibility Studies / Humans / Immunotherapy / Information management / Liver cancer / Liver Neoplasms / Lung cancer / Lung Neoplasms - drug therapy / Medical equipment / Medical personnel / Metastasis / Monitoring, Physiologic / Monoclonal antibodies / Multicenter Studies as Topic / Oncology / Outpatient care facilities / Patient satisfaction / Randomized Controlled Trials as Topic / Symptom management / Targeted cancer therapy / Telemedicine / Treatment Outcome